Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
← catalyst calendarSponsored by Candel Therapeutics, Inc. (industry) · CADL — their whole pipeline →. With Mayo Clinic.
Phase
Phase 2
Status
Unknown status
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
54estimated
Sites
3
Countries
Mexico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2015 | not stated | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2015-05-18 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-01-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Borderline Resectable Pancreatic Adenocarcinoma
Interventions
- Biological: Aglatimagene besadenovec — also filed as CAN-2409, AdV-tk
- Radiation: Chemoradiation
- Radiation: Stereotactic body radiation therapy
- Procedure: Surgery
Primary outcomes
what the primary-completion date above is the date OFSafety grade by CTCAE version 4.0
measured From the time of CAN-2409 administration to 30 days after the last dose of valacyclovir.
Survival Rate
measured 24 months
Permalink · CADL's whole pipeline · Catalyst calendar · Every registered study · What changed